Shopping Cart
- Remove All
- Your shopping cart is currently empty
MK-8318 is an effective and selective antagonist of the CRTh2 receptor (Ki: 5.0 nM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,120 | 10-14 weeks | |
50 mg | $2,780 | 10-14 weeks | |
100 mg | $3,700 | 10-14 weeks |
Description | MK-8318 is an effective and selective antagonist of the CRTh2 receptor (Ki: 5.0 nM). |
Targets&IC50 | CRTH2/DP2 receptor:5.0 nM (ki), cAMP:8.0 nM, CYP2D6:50 μM, CYP3A4:50 μM, β-arrestin:3.5 nM, CYP2C9:50 μM |
In vitro | MK-8318 suppresses β-arrestin, cAMP, CYP3A4, CYP2C9, and CYP2D6 (IC50s: 3.5±2.1 nM, 8.0±6.8 nM, 50 μM, 50 μM and 50 μM). |
In vivo | MK-8318 demonstrates 76% efficacy in late airway response (LAR) and 114% efficacy in airway hyperresponsiveness (AHR) by blocking LAR and AHR after intravenous infusion at 1 mg/kg in a sheep model. It also exhibits good efficacy on BAL cells/pulmonary function in ovalbumin-sensitized and -challenged Brown Norway rats at 3, 10, and 30 mg/kg oral dosing. |
Molecular Weight | 534.5 |
Formula | C27H26F4N2O5 |
Cas No. | 1416581-40-2 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.